Compare Novavax Inc (NVAX) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Snowflake Inc — how do they compare? Novavax Inc trades at $7.89 (market cap $1.31B), while Snowflake Inc trades at $337.73 (market cap $116.01B). The key difference: Snowflake Inc is far larger — about 88.6× Novavax Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | SNOW | |
|---|---|---|
Market Cap | $1.31B | $116.01B |
Sector | Health | Technology |
52-Week High | $11.19 | $334.70 |
52-Week Low | $6.22 | $121.11 |
Enterprise Value | $889.30M | $115.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Snowflake (SNOW) trades at $334.7, up 1.27% on the day, reflecting strong momentum amid a bullish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $0.39 exceeding expectations. Revenue growth remains robust, reaching $3.63 billion in 2025, though profitability challenges persist with a net income margin of -23.79%. Recent news highlights product innovations, including AI integrations and security enhancements, driving investor optimism.
Outlook is supported by Wall Street's bullish consensus, with 81% of analysts rating SNOW a buy and a price target of $302.18. However, high valuation multiples, intense competition, and ongoing losses present significant risks. The stock's proximity to its 52-week high suggests limited near-term upside without further positive catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
